Loading
A phase 1/2 trial of Giredestrant and Abemaciclib in HR-positive / HER2-negative breast cancer, run by Genentech, Inc., now recruiting.
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer is a phase 1/2 interventional study registered as NCT07100106 by Genentech, Inc., with 285 participants planned, started 2025-10-07 and due to reach its primary completion in 2028-08-31. Interventions recorded: GDC-4198, Giredestrant and Abemaciclib.
Shares Giredestrant, Flatiron Health (Roche), Abemaciclib, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Abemaciclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Flatiron Health (Roche), HR-positive metastatic breast cancer after CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.